Basket Study at St. Joseph Health Medical Group

St. Joseph Health Medical Group is currently enrolling patients for the following basket studies:

A Phase 1/2 Study of Galinpepimut-S in Combination with Pembrolizumab (MK-3475) in Patients with Selected Advanced Cancers (SELLAS)

Phase I/II

This is a open-label, multi-arm study of the Wilms Tumor-1 (WT1)-targeting multivalent heteroclitic peptide immunotherapeutic vaccine galinpepimut-S in combination with the programmed death-1 (PD1) inhibitor pembrolizumab in patients with selected advanced cancers. This study will assess the efficacy and safety of galinpepimut-S and pembrolizumab and investigate the effect of galinpepimut-S and pembrolizumab on various tumor types. Indications treated are colorectal (third or fourth line), ovarian (second or third line), small cell lung cancer (second line), breast cancer (triple negative; second line), acute myelogenous leukemia (unable to attain deeper morphological response than partial [PR] on hypomethylating agents and who are not eligible for allogeneic hematopoietic stem cell transplant).

Treatment agent: Galinpepimut-S (WT1 immunotx) + pembro
PI: Jarrod Holmes, MD
Study Coordinator: Sabine Ucik // Sabine.Ucik@stjoe.org // (707) 521-3830
Resources and Links: clinicaltrials.gov NCT No: NCT03761914